BioXcel Therapeutics, Inc.

DB:BX20 Stock Report

Market Cap: €29.7m

BioXcel Therapeutics Management

Management criteria checks 3/4

BioXcel Therapeutics' CEO is Vimal Mehta, appointed in Apr 2017, has a tenure of 9.25 years. total yearly compensation is $971.60K, comprised of 72.7% salary and 27.3% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth €67.24K. The average tenure of the management team and the board of directors is 5.5 years and 8 years respectively.

Key information

Vimal Mehta

Chief executive officer

US$971.6k

Total compensation

CEO salary percentage72.72%
CEO tenure9.3yrs
CEO ownership0.2%
Management average tenure5.5yrs
Board average tenure8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Vimal Mehta's remuneration changed compared to BioXcel Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$75m

Dec 31 2025US$972kUS$707k

-US$70m

Sep 30 2025n/an/a

-US$68m

Jun 30 2025n/an/a

-US$51m

Mar 31 2025n/an/a

-US$40m

Dec 31 2024US$1mUS$1m

-US$60m

Sep 30 2024n/an/a

-US$71m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$153m

Dec 31 2023US$5mUS$1m

-US$179m

Sep 30 2023n/an/a

-US$212m

Jun 30 2023n/an/a

-US$203m

Mar 31 2023n/an/a

-US$187m

Dec 31 2022US$5mUS$944k

-US$166m

Sep 30 2022n/an/a

-US$137m

Jun 30 2022n/an/a

-US$122m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$9mUS$917k

-US$107m

Sep 30 2021n/an/a

-US$102m

Jun 30 2021n/an/a

-US$100m

Mar 31 2021n/an/a

-US$94m

Dec 31 2020US$10mUS$890k

-US$82m

Sep 30 2020n/an/a

-US$69m

Jun 30 2020n/an/a

-US$54m

Mar 31 2020n/an/a

-US$41m

Dec 31 2019US$2mUS$459k

-US$33m

Compensation vs Market: Vimal's total compensation ($USD971.60K) is above average for companies of similar size in the German market ($USD481.69K).

Compensation vs Earnings: Vimal's compensation has been consistent with company performance over the past year.

CEO

Vimal Mehta (64 yo)

9.3yrs
Tenure
US$971,598
Compensation

Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...

Leadership Team

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder9.3yrsUS$971.60k0.23%
€ 67.2k
Richard Steinhart
Senior VP & CFO8.8yrsUS$394.65k0.085%
€ 25.3k
Javier Rodriguez
Senior VP5.5yrsUS$432.58k0.087%
€ 25.8k
Frank Yocca
Executive VP & Chief Scientific Officer2.6yrsUS$1.15m0.085%
€ 25.2k
Mark Pavao
Acting Chief Commercial Officerless than a yearno datano data
Matt Mandel
Vice President of Clinical Developmentno datano datano data
5.5yrs
Average Tenure
64yo
Average Age

Experienced Management: BX20's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vimal Mehta
Founder9.3yrsUS$971.60k0.23%
€ 67.2k
Steven Paul
Member of Advisory Boardno datano datano data
Peter Mueller
Independent Chairman & Lead Director9.3yrsUS$130.00k0.038%
€ 11.2k
Alan Breier
Member of Clinical Advisory Board8yrsno datano data
Thomas Laughren
Member of Clinical Advisory Board7.4yrsno datano data
Maurizio Fava
Member of Clinical Advisory Board7.4yrsno datano data
Stephen Marder
Member of Clinical Advisory Board8yrsno datano data
Sheldon Preskorn
Member of Clinical Advisory Board8yrsno datano data
John Krystal
Member of Clinical Advisory Board7.4yrsno datano data
Sandeep Laumas
Independent Director8.8yrsUS$92.50k0%
€ 0
Sheila Gujrathi
Member of Advisory Boardno datano datano data
George Grossberg
Member of Clinical Advisory Board8yrsno datano data
8.0yrs
Average Tenure
64yo
Average Age

Experienced Board: BX20's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 06:21
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioXcel Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Guyn KimBMO Capital Markets Equity Research
Alec StranahanBofA Global Research